Extended Data Fig. 3: Progression-free Survival in PD-L1 + patients. | Nature Medicine

Extended Data Fig. 3: Progression-free Survival in PD-L1 + patients.

From: Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial

Extended Data Fig. 3

Kaplan-Meier estimates of PFS as assessed by a blinded independent review committee according to RECIST v1.1 are shown to compare the toripalimab plus chemotherapy arm with the placebo plus chemotherapy arm in PD-L1 + patients. PD-L1 positive status was defined as the presence of membrane staining of any intensity in ≥1% of tumor cells or immune cells by JS311 IHC staining. Censored patients are marked with “┃” in the graph. Numbers of patients at risk at indicated time points are shown below the x-axis. Number of events, median PFS and stratified hazard ratio for disease progression or death are shown to the right of Kaplan-Meier curves. The hazard ratio was computed using the Cox proportional hazards model. The p-value was two-sided with no adjustment of multiplicity and computed using the unstratified log-rank test.

Back to article page